Evidence map›Paper›PMID 27388489›Full record

ArticlePloS one2016

A Novel Method and Its Application to Measuring Pathogen Decay in Bioaerosols from Patients with Respiratory Disease.

Graham R Johnson, Luke D Knibbs, Timothy J Kidd, Claire E Wainwright, Michelle E Wood, Kay A Ramsay, Scott C Bell, Lidia Morawska

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Biorisk Management Features of a Temporary COVID-19 Hospital.Applied biosafety : journal of the American Biological Safety Association · 2023
    Article
  3. Short-Term Use Biocontainment Bubbles: Innovative Source Containment of Potentially Infectious SARS-CoV-2 Aerosols.Applied biosafety : journal of the American Biological Safety Association · 2022
    Article
  4. The Effectiveness of Ultraviolet-C (UV-C) Irradiation on the Viability of AirborneInternational journal of environmental research and public health · 2022
    Article
  5. Article
  6. Journal of the Royal Society, Interface · 2021
    Article
  7. Reply to Zuckerman and Saiman: Use of Masks in Patients with Cystic Fibrosis.American journal of respiratory and critical care medicine · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Graham R JohnsonInternational Laboratory for Air Quality and Health (ILAQH), Queensland University of Technology (QUT), Brisbane, Queensland, Australia.ORCID http://orcid.org/0000-0001-6874-0230
Luke D KnibbsSchool of Public Health, The University of Queensland, Herston, Queensland, Australia.
Timothy J KiddChild Health Research Centre, The University of Queensland, Herston, Queensland, Australia.
Claire E WainwrightSchool of Medicine, The University of Queensland, Herston, Queensland, Australia.
Michelle E WoodLung Bacteria Research Group, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Kay A RamsaySchool of Medicine, The University of Queensland, Herston, Queensland, Australia.
Scott C BellSchool of Medicine, The University of Queensland, Herston, Queensland, Australia.
Lidia MorawskaInternational Laboratory for Air Quality and Health (ILAQH), Queensland University of Technology (QUT), Brisbane, Queensland, Australia.
The University of Queensland · AUQueensland University of Technology · AUQIMR Berghofer Medical Research Institute · AUQueen's University Belfast · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This work aimed to develop an in vivo approach for measuring the duration of human bioaerosol infectivity. To achieve this, techniques designed to target short-term and long-term bioaerosol aging, were combined in a tandem system and optimized for the collection of human respiratory bioaerosols, without contamination. To demonstrate the technique, cough aerosols were sampled from two persons with cystic fibrosis and chronic Pseudomonas aeruginosa infection. Measurements and cultures from aerosol ages of 10, 20, 40, 900 and 2700 seconds were used to determine the optimum droplet nucleus size for pathogen transport and the airborne bacterial biological decay. The droplet nuclei containing the greatest number of colony forming bacteria per unit volume of airborne sputum were between 1.5 and 2.6 μm. Larger nuclei of 3.9 μm, were more likely to produce a colony when impacted onto growth media, because the greater volume of sputum comprising the larger droplet nuclei, compensated for lower concentrations of bacteria within the sputum of larger nuclei. Although more likely to produce a colony, the larger droplet nuclei were small in number, and the greatest numbers of colonies were instead produced by nuclei from 1.5 to 5.7 μm. Very few colonies were produced by smaller droplet nuclei, despite their very large numbers. The concentration of viable bacteria within the dried sputum comprising the droplet nuclei exhibited an orderly dual decay over time with two distinct half-lives. Nuclei exhibiting a rapid biological decay process with a 10 second half-life were quickly exhausted, leaving only a subset characterized by a half-life of greater than 10 minutes. This finding implied that a subset of bacteria present in the aerosol was resistant to rapid biological decay and remained viable in room air long enough to represent an airborne infection risk.

Indexed as

AerosolsAir MicrobiologyAdultCoughCystic FibrosisHumansInhalation ExposureMalePseudomonas aeruginosaPseudomonas InfectionsRespirationRespiration DisordersSputumTime FactorsYoung AdultAerosols

Identifiers

PMID27388489
PMCPMC4936712
OpenAlexW2469657567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.